Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms Abstract #2173

Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with an increased incidence reported in recent years. Researchers have shown that tumor cells produce and secrete more exosomes compared with normal cells. Serum amyloid A1 (SAA1) is elevated in patients with liver cancer, lung cancer, breast cancer, prostate cancer and endometrial cancer. However, the relation between SAA1 and GEP-NENs remains unclear.
Aim(s): To explore circulating exosomes biomarkers which may do favor for diagnosis and treatment to GEP-NENs, and evaluate their biological behavior accurately.
Materials and methods: Using iTraq analysis to identify 96 differentiated proteins from the circulating exosomes of the GEP-NENs patients and healthy subjects.To compare positive incidence of SAA1 in cancer tissues and peri-cancer tissues of 43 GEP-NENs patients by immunochemistry analysis.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: He Na
Authors: Na H, Qiyun T

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2144 Analysis of the Proteomics of Serum Circulating Exosomes in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms(GEP-NENs) are intractable, heterogeneous tumors, characterized by secreting serotonin metabolites or polypeptide hormones. There are currently little targets for the diagnosis and treatment of GEP-NENs. Serum circulating exosomes (scrExos) are extracellular vesicles secreted by all cells especially neuroendocrine cells to some extent, circulating in the blood with proteins and nucleic acids.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Bai Jian-An
Authors: Jian-An B, Qiyun T, Ye T
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#1278 Midkine is a New Novel Serum Biomarker in Small Intestinal Neuroendocrine Tumors (SI-NETs).
Introduction: SI-NETs are often diagnosed late, which limits curative treatment options.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Kosmas Daskalakis
Keywords: Biomarker, SI-NET
#2207 Circulating Neuroendocrine Gene Transcripts (NETest) Decrease Early after Radical Surgery: Preliminary Results of a Prospective Study
Introduction: Specific biomarkers for predicting response and risk of recurrence after surgery for enteropancreatic neuroendocrine tumours (EP-NETs) are still lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Francesca Muffatti